Results 111 to 120 of about 790,096 (261)

Exploring individualized crovalimab dosing in PNH through in silico modelling: Potential for improved convenience and cost efficiency

British Journal of Clinical Pharmacology, Volume 92, Issue 10, Page 3460-3465, October 2026.
Abstract Aim Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired haematopoietic stem cell disorder. Crovalimab, a complement C5‐inhibitor, is approved for PNH and can be self‐administered subcutaneously every 4 weeks, offering a more convenient route than intravenous C5‐inhibitors.
Mendy ter Avest, Simon E. Koele, Nicole C. A. J. van de Kar, Saskia M. C. Langemeijer, Rob ter Heine   +4 more
wiley   +1 more source

Acknowledgement to Reviewers of Pharmaceuticals in 2016

, 2017
The editors of Pharmaceuticals would like to express their sincere gratitude to the following reviewers for assessing manuscripts in ...
Pharmaceuticals Editorial Office
core   +1 more source

Biosimilar uptake in the United States: Examining state-level longitudinal trends in biosimilar filgrastim use and their association with biosimilar substitution policies [PDF]

, 2020
Thesis (Ph.D.)--University of Washington, 2020Defined as medicines manufactured in a living system, biologics have demonstrated high clinical utility for an array of therapeutic areas.
Grewal, Simrun Kaur
core  

Clinical evidence and implementation guidance for biosimilar switching in ankylosing spondylitis

Frontiers in Pharmacology
Biosimilar tumor necrosis factor inhibitors provide therapeutically equivalent alternatives to reference biologics for ankylosing spondylitis (AS) management at reduced costs.
Luoyang Cai, Xin Chen, Yangbin Fang, Li Li, Tao Liu, Zhenkun Gan, Zheng Zuo   +6 more
doaj   +1 more source

Cohort Study on Drug Survival and Tolerability of Adalimumab Biosimilar Transitioning: Pharmaceutical Properties Do Matter

Clinical Pharmacology & Therapeutics
There are no clinically meaningful differences between bio‐originators (BO) and their biosimilars (BS) in safety and efficacy. However, differences in pharmaceutical properties, such as volume and excipient, can occur. This study aimed to compare outcomes between patients transitioning from the modernized adalimumab BO (0.4 mL/no ...
Amy C.D. Peeters, Maike H.M. Wientjes, Wieland D. Müskens, David F. Ten Cate, Laura C. Coates, Bart J. F. van den Bemt, Noortje van Herwaarden, Alfons A. den Broeder   +7 more
openaire   +3 more sources

External Control Arms in Japan: A Systematic Case Analysis of Documented Regulatory Implementation and Uncertainty Management

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 1068-1080, October 2026.
External control arms (ECAs) have emerged as important tools to provide benchmark evidence on comparator effectiveness and thereby support regulatory decision making in situations where randomized controlled trials are difficult to conduct. However, how key methodological elements for ECAs are documented and implemented in practice and how residual ...
Suguru Okami, Alexandros Sagkriotis
wiley   +1 more source

Acknowledgement to Reviewers of Pharmaceuticals in 2017

, 2018
Peer review is an essential part in the publication process, ensuring that Pharmaceuticals maintains high quality standards for its published papers[...
Pharmaceuticals Editorial Office
core   +1 more source

Anti-resorptive therapy with denosumab in elderly and senile patients with osteoporosis: a narrative review and clinical recommendations

Consilium Medicum
Senile osteoporosis represents one of the most pressing challenges in modern geriatric medicine, characterized by high prevalence, delayed diagnosis, and severe complications such as low-energy fractures, which are associated with disability, loss of ...
Ekaterina N. Dudinskaya, Anton V. Naumov, Natalia O. Khovasova   +2 more
doaj   +1 more source

Biosimilar uptake by British local formularies: a cross sectional study

International Journal of Clinical Pharmacy, 2017
Background Biological medicines are starting to lose their patent protection, so similar, inexact copies (biosimilars) are being developed and licensed.
Saja A. Alnahar, R. Elliott, Murray D. Smith   +2 more
semanticscholar   +1 more source

Adverse Reactions Identified after Approval of Novel Medicines: Analysis of 339 New Molecular Entities and Therapeutic Biologics

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 1120-1128, October 2026.
Postmarketing safety surveillance data identify safety issues not identified in preapproval clinical trials. We describe the frequency of new safety issues overall and by labeling section and the relationship of the most commonly added safety issues with the cumulative number of prescriptions dispensed via retail pharmacies.
Ellen Pinnow, Brendan Day, Esther H. Zhou, Corinne Woods, Nana Dwumfour, Jenni Y. Lee, Ilynn Bulatao, Sanae Cherkaoui, Manish Kalaria, Sonja Brajovic, Nabila Sadiq, Farideh Sistani, Maggie Lee, Grace Chai, Gerald Dal Pan   +14 more
wiley   +1 more source